No Data
No Data
Erkang Pharmaceuticals: Semi-Annual Report 2024
Erkang Pharmaceuticals: 2024 Semi-Annual Report Summary
Hunan Er-Kang Pharmaceutical (300267.SZ) released its semi-annual performance, with a net income of 63.002 million yuan, a decrease of 87.87% year-on-year.
Hunan Er-Kang Pharmaceutical (300267.SZ) released its semi-annual report for 2024, with revenue of 6...
Hunan Er-Kang Pharmaceutical (300267.SZ): The net income in the first half of the year was 6.3002 million yuan, a year-on-year decrease of 87.87%.
hunan er-kang pharmaceutical (300267.SZ) announced its semi-annual report for the year 2024, with a reported revenue of 0.621 billion yuan, a decrease of 40.83% compared to the same period last year. The net income attributable to shareholders of the listed company was 6.3002 million yuan, a decrease of 87.87% compared to the same period last year. The net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 2.2647 million yuan, a decrease of 90.55% compared to the same period last year. The basic earnings per share was 0.0031 yuan.
Hunan Er-Kang Pharmaceutical Co., Ltd's (SZSE:300267) 28% Share Price Surge Not Quite Adding Up
A-share midday review: Shanghai Composite Index up 0.38%, with more than 3000 stocks rising. The sectors of vitamins, baijiu and real estate are among the top gainers.
As of the midday close, the Shanghai Composite Index rose 0.38% to 2880.61 points, the Shenzhen Component Index rose 0.49%, and the Chinext Price Index rose 0.09%.
No Data
No Data